Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but introduce non-trivial drug design parameters that must be considered as part of target selection and…
Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window for a promising therapy due to toxicity in non-target tissues. Bispecific drugs engineered to bind…
中国、韓国、日本にて開催されるサターラ主催フォーラムを通して、モデルを活かした医薬品開発(MIDD)アプローチを活用し新薬をより早く患者に届けることを目指す研究者の交流と情報交換を促進RADNOR, PA –…
The article from the European Journal of Pharmaceutical Sciences reviews the role of Physiologically Based Pharmacokinetic (PBPK) modeling in the FDA’s approval of novel drugs from 2019 to 2023. It…
Every year, the Consortium—comprising over 30 leading biopharmaceutical companies—convenes to discuss Physiologically Based Pharmacokinetic (PBPK) initiatives in drug development and their regulatory impacts. Consortium members collaborate closely with Simcyp scientists,…
© 2025 Certara. All Rights Reserved. | 個人情報保護
